treasure_map

Leaflets offering gold coins for paediatricians appear at Bengaluru event

January 23, 2017
Medical Communications, Sales and Marketing India, PEDICON

Pharmaceutical firms in India are not allowed to offer any kind of reimbursement for privileging certain treatment over others, this …

Artificial skin development has implications for clinical trials

January 23, 2017
Medical Communications, Sales and Marketing Seoul National University Hospital, artificial skin, dermatology

Researchers from Seoul National University Hospital have announced that it has developed a microchip that has been designed to replicate …

BMS receives $625 million patent settlement boost from Merck

January 23, 2017
Sales and Marketing BMS, MSD, Merck, keytruda, opdivo

Bristol-Myers Squibb were in desperate need of releasing good news after the brief announcement that it would no longer be …

mallinckrodt-project

Company in 85,000% infant epilepsy drug price increase receives $100 million fine

January 23, 2017
Sales and Marketing Mallinckrodt, Martin Skhreli

Mallinckrodt Pharmaceuticals has hit the headlines for particularly dispiriting reasons – with further evidence of practise by some companies that …

shutterstock_141105490

Asia-Pacific flu market to hit $1.71bn by 2022

January 20, 2017
Business Services, Medical Communications APAC, GBI Research

According to new data from intelligence provider GBI Research, the flu vaccines market in the Asia-Pacific (APAC) region is set …

biopsy

“Biggest leap in decades” for prostate cancer, 1 in 4 could avoid biopsies

January 20, 2017
Medical Communications, Research and Development Biposy, prostate cancer

A new study has estimated that one in four men could avoid unnecessary invasive biopsies to detect prostate cancer – …

J&J’s Imbruvica scores fifth FDA lymphoma approval

January 20, 2017
Medical Communications, Research and Development, Sales and Marketing FDA, Marginal Zone Lymphoma, imbruvica

Johnson & Johnson’s Imbruvica (ibrutinib) has scored its fifth indication approval in the US for the treatment of Marginal Zone …

4420456374_64a3d7e6aa

Top Ten most popular articles on Pharmafile.com this week

January 20, 2017
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing top ten

It’s Friday, and there have been some big revelations for the pharma industry this week. Brexit, the ever-present hot topic …

jenny_tragner_-_main

Pharmaceutical R&D tax credit regulatory legislation: The need for clarity

January 20, 2017
Medical Communications, Research and Development, Sales and Marketing R&D, pharmafile

Since their introduction in the UK in 2000, R&D tax credits have provided a significant boost to pharmaceutical and biotech …

Sanofi diabetes drug Sulinqua green-lighted in Europe

January 19, 2017
Research and Development, Sales and Marketing Sanofi, Sulinqua

Sanofi’s diabetes drug Suliqua has been granted marketing authorisation by the European Commission, giving the go ahead for the launch …

bi_german_building_at_night

Boehringer steps into Humira race with US and EU biosimilar filings

January 19, 2017
Sales and Marketing Boehringer Ingelheim, Humira, biosimilar

Boehringer Ingelheim has just stepped into the ring to battle it out for a slice of Humira’s revenue with accepted …

abbas-hussain

GSK snatches AZ Europe VP to replace exiting global head of pharma

January 19, 2017
Business Services, Medical Communications, Sales and Marketing Abbas Hussain, Luke Miels

GlaxoSmithKline has announced that its global head of pharmaceuticals Abbas Hussain (pictured) is leaving the company; the vacated role will …

allergan

Allergan fined £15m over failure to disclose merger discussions

January 19, 2017
Sales and Marketing Allergan, SEC

Allergan has been fined $15 million by the Security and Exchange Commission (SEC) after committing disclosure violations during merger talks …

headquarters_2_web

Lilly brings migraine drug home with $960m acquisition

January 19, 2017
Sales and Marketing CoLucid Pharmaceuticals, Eli Lilly

Eli Lilly has announced it is to shell out $960 million to snatch up CoLucid Pharmaceuticals and specifically its migraine …

shutterstock_159488225

Alcobra axes ADHD drug after Phase 3 failure

January 18, 2017
Research and Development ADHD, Alcobra, metadoxine

Israeli-based firm Alcobra is to pull the plug on its experimental attention deficit hyperactivity disorder (ADHD) drug metadoxine after it …

biogen_austria_238

Biogen shells out $1.25bn to protect best-selling MS drug

January 18, 2017
Research and Development, Sales and Marketing Biogen, Forward Pharma, multiple sclerosis, tecfidera

Biogen has announced it is to pay $1.25 billion to Copenhagen-based biotech Forward Pharma in the latest development in a …

bribe

Researchers financed by pharma more likely to produce positive results, new report says

January 18, 2017
Research and Development clinical trials

A new paper published in the British Medical Journal (BMJ) has called the integrity of certain clinical trials into question …

access_accelerated

22 pharma companies join forces for global non-communicable disease initiative

January 18, 2017
Research and Development BMS, Celgene, Eisai, Eli Lilly, GSK, J&J, JJ, MSD, Merck, Novartis, Pfizer, Roche, Sanofi, Takeda

The World Economic Forum Annual Meeting in Switzerland has seen the launch of Access Accelerated, a global initiative consisting of …

theresa_may

PM May announces Brexit plan, BioIndustry Association CEO reacts

January 18, 2017
Research and Development, Sales and Marketing Theresa May, brexit

After months of uncertainty following the UK’s vote to leave the EU, Theresa May has finally announced the first inklings …

shutterstock_206748499

Centre for Process Innovation to support pharma SMEs

January 17, 2017
Manufacturing and Production, Medical Communications, Research and Development CPI, Centre for Process Innovation

The Centre for Process Innovation is targeting small and medium-sized enterprises from the pharmaceutical and chemical industries with its Innovation …

The Gateway to Local Adoption Series

Latest content